Value in health regional issues最新文献

{"title":"Cost-Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Among Adults in the Philippines","authors":"Joel Santiaguel MD ,&nbsp;Ahuva Averin MPP ,&nbsp;Winniefer Nua MSc ,&nbsp;Mark Atwood MS ,&nbsp;Liping Huang MD ,&nbsp;Dhwani Hariharan PhD ,&nbsp;Josephine Guerrero MD ,&nbsp;Ricardo Zotomayor MD ,&nbsp;Aileen David-Wang MD","doi":"10.1016/j.vhri.2025.101095","DOIUrl":"10.1016/j.vhri.2025.101095","url":null,"abstract":"<div><h3>Objectives</h3><div>The Philippine National Immunization Program guidelines recommend using the 23-valent pneumococcal polysaccharide vaccine (PPV23) among senior citizens. We conducted cost-effectiveness analyses to assess the impact of replacing 2-dose PPV23 with PCV13 in all adults aged ≥60 years and expanding the recommendation to include PCV13 for adults aged 18 to 59 years at elevated risk of disease (moderate-/high-risk).</div></div><div><h3>Methods</h3><div>Lifetime risks and costs of invasive pneumococcal disease, nonbacteremic pneumococcal pneumonia (NBPP), and expected impact of vaccination were projected using a probabilistic cohort model. Base-case analyses compared PCV13 with 2-dose PPV23 (PPV23 + PPV23) among older adults (60-99y). Scenario analyses evaluated PCV13 use among older and moderate-/high-risk adults aged 18 to 59 years versus a combined strategy (18-49 y: no vaccine; 50-59 y: single-dose PPV23; 60-99 y: PPV23 + PPV23). Cost per quality-adjusted life year (QALY) gained was evaluated from healthcare system and societal perspectives (discounting 7%/year). Deterministic and probabilistic sensitivity analyses were conducted.</div></div><div><h3>Results</h3><div>In the base case, PCV13 instead of PPV23 + PPV23 would reduce cases of invasive pneumococcal disease by 698, NBPP by 915, and deaths by 333 among adults aged 60 to 99 years (<em>N</em> = 10 583 924). With QALYs higher by 848 and net societal (ie, direct + indirect) costs of ₱26.2 million, cost per QALY was ₱30 855. PCV13 was cost-effective in 98.8% of 1000 probabilistic sensitivity analyses simulations in the base-case population. In scenario analyses, PCV13 was also cost-effective (₱423 770/QALY).</div></div><div><h3>Conclusions</h3><div>Findings support replacing the two-dose PPV23 recommendation with 1 dose of PCV13 in adults aged ≥60 years and expanding the recommendation to include the use of PCV13 among moderate-/high-risk adults aged 18 to 59 years.</div></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"47 ","pages":"Article 101095"},"PeriodicalIF":1.4,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143593156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Economic and Disease Burden of Multiple Sclerosis in Colombia","authors":"Ana Lozano MD, MSc ,&nbsp;Juan Camilo Gutiérrez-Clavijo MSc ,&nbsp;Jean Carlo Pineda-Lozano OT ,&nbsp;Simón Cárdenas-Robledo MD ,&nbsp;Adriana Casallas-Vanegas MD ,&nbsp;Nelson J. Alvis-Zakzuk BEcon, MSc","doi":"10.1016/j.vhri.2025.101096","DOIUrl":"10.1016/j.vhri.2025.101096","url":null,"abstract":"<div><h3>Objectives</h3><div>Multiple sclerosis (MS) is a debilitating condition that primarily affects young adults. The recent development of more effective yet costly drugs aimed at delaying the progression of the disease further adds to the necessity of evaluating the costs associated with MS from the societal perspective and the disease burden. We aimed to estimate the disease and economic burden of MS from the societal perspective in Colombia during 2020.</div></div><div><h3>Methods</h3><div>The disease burden was estimated following the methodology proposed by Global Burden of Disease Study 2019. Regarding the economic burden, an average cost per patient was estimated and applied to national MS cases. Specifically, the average direct medical costs per patient were obtained from an insurance company’s database and validated by 2 clinical experts. Nonmedical direct and indirect costs were estimated based on the data collected from a sample of MS patients.</div></div><div><h3>Results</h3><div>Colombia lost an estimated 3455 disability-adjusted life years because of MS in 2020. The disease burden was mainly attributed to deaths (65.5%, 2264 years of life lost). Disability-adjusted life years were 1.7 times higher in women than in men. Risaralda was the municipality with the highest population-adjusted MS disease burden, followed by Bogotá, DC. The associated cost of MS was USD $88.2 million, of which 88% was attributed to direct medical costs.</div></div><div><h3>Conclusions</h3><div>MS is a high-cost disease in Colombia with an increasing prevalence. The results presented in this study will help determine the allocation of resources when planning health care services.</div></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"47 ","pages":"Article 101096"},"PeriodicalIF":1.4,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143580419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mapping KDQOL-36 Onto EQ-5D-5L and SF-6Dv2 in Patients Undergoing Dialysis in China","authors":"Zeyuan Chen BA ,&nbsp;Li Yang PhD ,&nbsp;Ye Zhang PhD","doi":"10.1016/j.vhri.2025.101103","DOIUrl":"10.1016/j.vhri.2025.101103","url":null,"abstract":"<div><h3>Objectives</h3><div>To develop mapping algorithms based on Kidney Disease Quality of Life-36 (KDQOL-36) scores to the EQ-5D-5L and SF-6Dv2 utility values among dialysis patients in China.</div></div><div><h3>Methods</h3><div>We used data from a cross-sectional multicenter survey in China to map the KDQOL-36 to the EQ-5D-5L and SF-6Dv2. The conceptual overlap between the KDQOL-36 and the EQ-5D-5L or SF-6Dv2 was evaluated using Spearman’s correlation coefficients. Direct mapping, including ordinary least squares, generalized linear model, beta regression model, Tobit regression model (TRM), censored least absolute deviations model, adjusted limited dependent variable mixture model (ALDVMM), response mapping, and seemingly unrelated ordered probit model, were used to derive mapping functions using the data set. Model performance was assessed by the mean absolute error (MAE) and root mean square error (RMSE) using cross-validation.</div></div><div><h3>Results</h3><div>A total of 378 patients (50.53% female; mean [SD] age: 49.05 [13.34]) were included in this study. The mean utility values of EQ-5D-5L and SF-6Dv2 were 0.72 and 0.57, respectively. When mapping to the EQ-5D-5L, the ALDVMM with 1 component was the best-performing model (MAE = 0.1579, RMSE = 0.2289). When mapping to SF-6Dv2, TRM was the best-performing model (MAE = 0.1108, RMSE = 0.1508). Generally, KDQOL-36 subscale scores and their squares were the optimal predictor set for each model. Overall, the models using KDQOL-36 subscale scores showed a better fit than those using the Kidney Disease Component Summary.</div></div><div><h3>Conclusions</h3><div>The ALDVMM and TRM models with the KDQOL-36 scores can be used to predict the EQ-5D-5L and SF-6Dv2 utility values, respectively, among dialysis patients in China.</div></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"48 ","pages":"Article 101103"},"PeriodicalIF":1.4,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143577881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-Reported Experience and Outcome Measures of Patients Living With Diabetes: Associations Among Different Factors","authors":"Eszter Sághy MRes ,&nbsp;Dalma Erdősi MSc ,&nbsp;Bertalan Németh PhD ,&nbsp;Sándor Kovács PhD ,&nbsp;István Wittmann PhD ,&nbsp;Antal Zemplényi PhD","doi":"10.1016/j.vhri.2025.101082","DOIUrl":"10.1016/j.vhri.2025.101082","url":null,"abstract":"<div><h3>Objectives</h3><div>This study aimed to explore the association between demographic characteristics and patient-reported experiences (PREs) and patient-reported outcomes (PROs) in individuals living with diabetes, using the Swedish National Diabetes Register questionnaire. The study sought to understand how baseline attributes such as age, gender, and education affect patients’ experiences and management of diabetes.</div></div><div><h3>Methods</h3><div>We used a cross-sectional survey approach with 544 patients diagnosed as having type 1 or type 2 diabetes mellitus at the University of Pécs. An exploratory factor analysis was conducted to identify the key dimensions of diabetes-related experiences, followed by a confirmatory factor analysis to validate these dimensions. Regression analysis was used to examine the impact of demographic variables on the derived factors.</div></div><div><h3>Results</h3><div>The factor analysis revealed 5 key dimensions: diabetes-related obstacles, diabetes coping mechanisms, flexibility of healthcare providers, general well-being, and social support. Regression analysis indicated that older patients perceived fewer obstacles and demonstrated better coping mechanisms. Higher educational levels were significantly associated with greater satisfaction with healthcare provider flexibility. Females reported poorer overall well-being but better coping mechanisms than males.</div></div><div><h3>Conclusions</h3><div>The findings suggest that demographic characteristics significantly influence patient experiences and outcomes in diabetes care. Tailored interventions that address specific demographic needs can enhance patient-centered care and improve management strategies. These insights underscore the importance of considering patient diversity in developing healthcare interventions and underscore the utility of the Swedish National Diabetes Register questionnaire in assessing diverse patient experiences in diabetes management.</div></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"47 ","pages":"Article 101082"},"PeriodicalIF":1.4,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143563595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estimation of the Effects and Costs of Lifestyle Intervention and Treatment With Voglibose in the Japanese Prediabetic Population: A Cost-Effectiveness Analysis","authors":"Mio Ezura PharmD ,&nbsp;Shota Saito PhD ,&nbsp;Masahiro Ishizawa MD, PhD ,&nbsp;Kazuya Fujihara MD, PhD ,&nbsp;Hirohito Sone MD, PhD ,&nbsp;Kohei Akazawa PhD","doi":"10.1016/j.vhri.2025.101098","DOIUrl":"10.1016/j.vhri.2025.101098","url":null,"abstract":"<div><h3>Objectives</h3><div>Prediabetes is a condition in which blood glucose levels are higher than normal but not high enough for a type 2 diabetes (T2DM) diagnosis. Lifestyle and pharmacological interventions, such as voglibose, an alpha-glucosidase inhibitor that reduces postprandial hyperglycemia, can address pathophysiological deficits in prediabetes. In Japan, voglibose is approved for preventing T2DM in patients with impaired glucose tolerance. We evaluated the cost-effectiveness of a lifestyle intervention alone and a combined intervention (lifestyle + voglibose) in extending quality-adjusted diabetes-free life years (QADFLY) and the associated costs in the Japanese prediabetic population.</div></div><div><h3>Methods</h3><div>We developed a Markov microsimulation model to replicate the natural history of a theoretical cohort of the Japanese prediabetic population. Transition probabilities were derived from the results of current clinical practices regarding prediabetes. Health outcomes were measured in the number of QADFLYs gained. Model robustness was addressed through one-way sensitivity analysis. The costs and QADFLYs were discounted at a rate of 2% per year.</div></div><div><h3>Results</h3><div>In the base case, the lifestyle intervention cost $4969 with 3.976 QADFLYs, compared with $5407 and 4.274 QADFLYs for the combined intervention. Prediabetic individuals in Japan would spend an additional $1469 to gain one more QADFLY when voglibose is added to lifestyle intervention.</div></div><div><h3>Conclusions</h3><div>The combined intervention is cost-effective, leading to more patients achieving normal glucose tolerance and fewer progressing to T2DM compared with lifestyle changes alone. In the Japanese prediabetic population, combining lifestyle changes with voglibose should be considered an effective strategy for preventing T2DM.</div></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"47 ","pages":"Article 101098"},"PeriodicalIF":1.4,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143563594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disparities in Out-of-Pocket Expenditures Among Hospitalized Patients With COVID-19 in Iran: A Decomposition Analysis of Inequality.","authors":"Ahmad Dehghani Ahmadabad, Sayyed Morteza Hosseini Shokouh, Parisa Mehdizadeh, Mohammad Meskarpour Amiri Ara","doi":"10.1016/j.vhri.2025.101093","DOIUrl":"https://doi.org/10.1016/j.vhri.2025.101093","url":null,"abstract":"<p><strong>Objectives: </strong>Limited information is available on the extent of inequality in out-of-pocket (OOP) expenditures among patients with COVID-19 in Iran and the factors contributing to this disparity. This study aimed to examine the inequality in OOP expenditures among hospitalized patients with COVID-19 and identify the associated factors.</p><p><strong>Methods: </strong>This study used the Gini coefficient as the primary measure of inequality in OOP expenditures among hospitalized patients with COVID-19. The analysis was conducted using Stata 16 software, supplemented by the Distributive Analysis Stata Package extension. The Gini coefficient was calculated to quantify the degree of inequality and was visualized using graphs. To examine the Gini coefficient across population subgroups, a Distributive Analysis Stata Package extension, the diginig module, was used.</p><p><strong>Results: </strong>Analysis of the Lorenz curve and the calculated Gini coefficient (0.69) confirmed the presence of inequality in OOP expenditures among hospitalized patients with COVID-19. Additionally, examination of inequality across population subgroups revealed that insurance status and type, clinical characteristics, and temporal patterns of hospitalization significantly contributed to the observed disparities in OOP expenditures among patients with COVID-19.</p><p><strong>Conclusions: </strong>This study highlights the enduring impact of insurance status, clinical characteristics, and temporal patterns of hospitalization on the financial burden. The findings emphasize the need for targeted interventions to reduce financial barriers and promote equitable access to care, thus offering important insights for managing future public health crises.</p>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":" ","pages":"101093"},"PeriodicalIF":1.4,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143543456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Understanding What Matters: Stakeholder Views on Decision Criteria for Cancer Drug Selection in the Public Sector in Malaysia","authors":"Haarathi Chandriah MPharm (Clin) ,&nbsp;Asrul Akmal Shafie PhD ,&nbsp;Muthukkumaran Thiagarajan MD, MClinOncol","doi":"10.1016/j.vhri.2024.101052","DOIUrl":"10.1016/j.vhri.2024.101052","url":null,"abstract":"<div><h3>Objective</h3><div>This study aimed to determine stakeholders’ decision criteria preferences for formulary decisions of cancer drugs in the Ministry of Health. The secondary objective was to identify the outcome measures of interest for assessment of clinical benefits for cancer drugs.</div></div><div><h3>Methods</h3><div>A survey questionnaire was administered online and as hard copy using purposive sampling to 32 healthcare facilities providing cancer services and the Formulary Management Branch in the Ministry of Health. Respondents reported whether a criterion “will be considered” and weighted its relative importance on a 5-point scale. The choice of safety and efficacy/effectiveness outcomes were ranked from 1 to 5, and the minimum value of benefit for the efficacy/effectiveness outcome ranked 1 was provided. Trade-offs between survival and quality of life were also explored. Inferential statistics were used to explore difference in responses.</div></div><div><h3>Results</h3><div>A total of 316 healthcare professionals responded to the survey. The most important criteria for value assessment of cancer drug were safety and effectiveness. Other criteria deemed important were quality of evidence, disease severity, and patient-reported outcomes. There was no difference in the criteria preference and weights across the various respondent groups. Overall survival was the most preferred clinical benefit outcome. Overall, willingness to pay was higher for life-prolonging treatment than treatment that improved quality of life.</div></div><div><h3>Conclusions</h3><div>This study revealed that a wide range of criteria beyond the traditional decision-making criteria of efficacy, safety, and cost-effectiveness are important for value assessment of cancer drugs for the purpose of formulary decisions.</div></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"46 ","pages":"Article 101052"},"PeriodicalIF":1.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142584405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the Potential Health and Economic Benefits of Optimized Low-Density Lipoprotein Cholesterol Management in Malaysia’s Atherosclerotic Cardiovascular Disease Population: A Model-Based Analysis","authors":"Chee Yoong Foo MBBS, PhD ,&nbsp;Nurul Azwani Nadia Mansor BEng ,&nbsp;Thurston Erng MBBS, MRCP ,&nbsp;Mohd Sapawi Mohamed MD, MMed ,&nbsp;Gurudevan Mahadevan MBBS, MRCP ,&nbsp;Glendon Lau MBBS, MRCP ,&nbsp;Asri Ranga MD, MMed ,&nbsp;Tiong Kiam Ong MBBS, MRCP","doi":"10.1016/j.vhri.2024.101059","DOIUrl":"10.1016/j.vhri.2024.101059","url":null,"abstract":"<div><h3>Objectives</h3><div>This study quantified the health and economic benefits of improving low-density lipoprotein cholesterol (LDL-C) control in Malaysian patients with established atherosclerotic cardiovascular disease (ASCVD). It aimed to inform policy discussions and healthcare planning for effective ASCVD management.</div></div><div><h3>Methods</h3><div>A deterministic, prevalence-based model was used to project the annual health burden and direct medical costs associated with recurrent ASCVD events over a 10-year horizon. The target population included adults (≥30 years) with established ASCVD and uncontrolled LDL-C levels (&gt;1.8 mmol/L). The model comprised 3 modules: population size projection, recurrent ASCVD risk calculation (by means of the Secondary Manifestations of ARTerial disease [SMART] risk model), and direct medical and productivity cost estimation. The current status quo and a scenario with a 50% improvement in mean LDL-C were compared.</div></div><div><h3>Results</h3><div>We projected over 800 000 adults with established ASCVD in 2023, increasing to approximately 1.4 million by 2032. Under the status quo, about 55 000 recurrent ASCVD events were expected within 10 years, with significant direct medical costs and productivity losses. Improved LDL-C control could potentially reduce recurrent events by 7000 cases (13% reduction), prevent 2100 premature deaths, and save approximately 32 400 years of life. Economically, this could lead to a reduction of approximately 72 million MYR in direct medical costs and a gain of approximately 132.4 million MYR in productivity over a decade.</div></div><div><h3>Conclusions</h3><div>Optimizing LDL-C control in high-risk patients with ASCVD presents a critical opportunity to reduce health and economic burdens in Malaysia.</div></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"46 ","pages":"Article 101059"},"PeriodicalIF":1.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142711054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Health-Related Quality of Life in a Slovak Representative Sample: A Validation Study of the Short Form-8 Scale","authors":"Dana Purova MSc ,&nbsp;Jana Furstova MSc, PhD ,&nbsp;Natalia Kascakova MD, PhD ,&nbsp;Alena Dobrotkova MSc, PhD ,&nbsp;Dagmar Sigmundova MSc, PhD ,&nbsp;Jozef Hasto MD, PhD ,&nbsp;Peter Tavel MSc","doi":"10.1016/j.vhri.2024.101058","DOIUrl":"10.1016/j.vhri.2024.101058","url":null,"abstract":"<div><h3>Objectives</h3><div>The Short Form-8 (SF-8) is a widely used 8-item tool for health-related quality of life assessment. This study aimed to evaluate the psychometric properties of the Slovak version of the SF-8 in a population sample.</div></div><div><h3>Methods</h3><div>A cross-sectional survey on a Slovak representative sample (n = 1018; mean age 46.24 ± 16.56 years; 51.3% women) monitoring health and well-being was performed in 2019. Exploratory network analysis and confirmatory factor analysis were used to assess the construct validity of the scale. Reliability and sociodemographic differences were evaluated.</div></div><div><h3>Results</h3><div>A 2-factor model had an adequate fit to the data [χ²(19) = 186.2, <em>P</em> &lt; .001, comparative fit index = 0.998, Tucker-Lewis index = 0.997, root mean square error of approximation = 0.093, standardized root mean of residuals = 0.039], with high reliability (α = 0.93, ω = 0.95). The physical component score and mental component score (MCS) were negatively associated with the presence of chronic health conditions. Lower physical component score and MCS were associated with higher age (<em>P</em> &lt; .001), and lower MCS were associated with female gender (<em>P</em> &lt; .001).</div></div><div><h3>Conclusions</h3><div>The Slovak version of the SF-8 represents a valuable tool for measuring health-related quality of life in the Slovak population in both practice and research.</div></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"46 ","pages":"Article 101058"},"PeriodicalIF":1.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142711055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-Utility Analysis of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Chemotherapy Regimen in Comparison With Gemcitabine and Cisplatin Chemotherapy Regimen in the Treatment of Patients With Muscle Invasive Bladder Cancer in Iran","authors":"Sadra Nadimi Parashkouhi PharmD ,&nbsp;Iman Karimzadeh PhD ,&nbsp;Alireza Rezvani MD ,&nbsp;Hadi Abbasian PhD ,&nbsp;Leila Zarei PhD","doi":"10.1016/j.vhri.2024.101051","DOIUrl":"10.1016/j.vhri.2024.101051","url":null,"abstract":"<div><h3>Objectives</h3><div>Bladder cancer incurs the highest lifetime treatment cost per patient among various cancers. Current guidelines endorse several cisplatin-based regimens as neoadjuvant chemotherapy. This cost-utility analysis aimed to compare 2 primary neoadjuvant chemotherapy regimens—dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) and gemcitabine and cisplatin (GC)—for patients with muscle-invasive bladder cancer, providing economic evidence to inform treatment guidelines in Iran.</div></div><div><h3>Methods</h3><div>A Markov decision model was constructed, incorporating 4 states: after radical cystectomy without recurrence, no radical cystectomy, recurrence, and death over a lifetime horizon. Clinical outcomes were derived from the VESPER (French Genito-Urinary Tumor Group and French Association of Urology V05) phase 3 randomized controlled trial, whereas costs were obtained from local Iranian data. The main result involved determining an incremental cost-effectiveness ratio within the simulated population, with a willingness-to-pay threshold of 1656 USD (equivalent to Iran’s gross domestic product per capita in 2023). Costs and benefits were discounted at 5.8% per annum, and probabilistic and univariate deterministic sensitivity analyses were conducted.</div></div><div><h3>Results</h3><div>From the perspective of the Iranian healthcare payer, 6 cycles of dd-MVAC yielded 0.02 greater quality-adjusted life-years compared with 4 cycles of GC, resulting in a cost saving of 1 173 491 USD and an incremental cost-effectiveness ratio of −78 708 870. Consequently, dd-MVAC emerged as the dominant option over a lifetime horizon (23 years). The model proved most sensitive to variations in recurrence and toxicity probabilities during treatment.</div></div><div><h3>Conclusions</h3><div>Based on this study’s results, dd-MVAC represents a cost-saving treatment regimen per patient in the Iranian health system compared with GC, with superior utility.</div></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"46 ","pages":"Article 101051"},"PeriodicalIF":1.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142547768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}